EntryPoint Capital LLC purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 32,425 shares of the company's stock, valued at approximately $378,000.
Other large investors also recently modified their holdings of the company. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics in the 4th quarter valued at about $40,000. Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after purchasing an additional 2,299 shares during the period. KBC Group NV lifted its stake in shares of Intellia Therapeutics by 62.4% during the 4th quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after buying an additional 2,340 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new position in Intellia Therapeutics in the 3rd quarter worth approximately $151,000. Hedge funds and other institutional investors own 88.77% of the company's stock.
Insider Buying and Selling
In other news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 29,000 shares of company stock worth $352,551 in the last 90 days. 3.20% of the stock is owned by company insiders.
Intellia Therapeutics Trading Down 11.9 %
Shares of NTLA stock traded down $0.96 during trading hours on Monday, hitting $7.11. 6,673,646 shares of the company's stock were exchanged, compared to its average volume of 2,207,709. The company has a market capitalization of $736.01 million, a PE ratio of -1.31 and a beta of 1.97. Intellia Therapeutics, Inc. has a 12-month low of $6.98 and a 12-month high of $28.18. The business's 50 day simple moving average is $9.93 and its 200-day simple moving average is $13.63.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on NTLA shares. Wedbush reissued a "neutral" rating and set a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. HC Wainwright started coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They set a "buy" rating and a $30.00 price objective on the stock. Citigroup raised their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company lowered their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, BMO Capital Markets decreased their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $37.56.
Get Our Latest Analysis on NTLA
Intellia Therapeutics Profile
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Articles
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
